Trade CTNM stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Contineum Therapeutics, Inc. Class A (CTNM) is trading at US$13.53, up 2.42% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$646.71M. Over the past 52 weeks, CTNM has traded between US$8.60 and US$17.79. On Syfe you can trade CTNM with $0 commission and add it to your watchlist.
| Previous close | US$13.21 |
|---|---|
| Market cap | US$646.71M |
| 52-week range | US$8.60 – US$17.79 |
| Volume | 2.14M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.
Year: 2024
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
Aug 17, 3:01 PM · MT Newswires
Contineum Therapeutics, Inc. Class A (CTNM) stock is trading at US$13.53, +2.42% from the previous close of US$13.21.
The market cap for Contineum Therapeutics, Inc. Class A (CTNM) stock is approximately US$646.71M.
The 52-week high for Contineum Therapeutics, Inc. Class A (CTNM) stock is US$17.79.
The 52-week low for Contineum Therapeutics, Inc. Class A (CTNM) stock is US$8.60.
Contineum Therapeutics, Inc. Class A (CTNM) does not currently pay a dividend.
Stay on top of CTNM
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
